21
KIT
traditional point-in-time glucose
monitoring methods. However,
several challenges remain such
as consistency in accuracy, the
need for calibration, and concerns
related to comfort and wearability.
American company Glucotrack
is investigating a novel approach
that draws from both continuous
glucose monitoring and blood
glucose monitoring methodologies.
Its investigational system is being
developed with the goal of combining
the direct measurement of blood
glucose with the data frequency
of continuous monitoring, while
seeking to overcome some of the
limitations associated with wearable
technologies.
Glucotrack is developing a
fully implantable investigational
continuous blood glucose monitoring
(CBGM) system-a small device
designed to be placed under the
skin and evaluated for its ability to
continuously measure blood glucose
for up to three years. The system is
being evaluated for its potential to
reduce calibration needs and address
challenges related to comfort and
wearability often associated with
current CGM technologies.
With a focus on people-centered
design, the company's goal is to
create a solution that may help make
glucose monitoring less burdensome
for individuals living with diabetes.
Just in the US.
glucotrack.com
Roche
Using continuous glucose monitoring
(CGM) often leads to greatly
improved diabetes management,
but readings are only part of the
equation. Glucose predictions can
help people get ahead of highs and
lows - before they occur.
Roche has received approval
in Europe to pair its Accu-Chek
SmartGuide CGM with the mySugr
app. The move brings SmartGuide's
forecasting into an app used by many
people with diabetes worldwide.
The algorithm provides 30-minute
and two-hour forecasts, along with
a seven-hour overnight low-risk
prediction.
Recent study data showed the
system's Night Low Predict feature
was associated with a 20% reduction
in any nighttime hypoglycaemia and
a 31% reduction in severe (less than
54 mg/dL) hypoglycaemia at night.
Based on new research, pairing
the SmartGuide CGM with the
mySugr app could help reduce
hypoglycaemia risk and reduce
diabetes distress in an app familiar to
many people with diabetes. Currently
only available in select countries,
Roche is planning a bigger rollout of
its CGM to more than 30 countries
by the end of 2025. As As reported
by Diatribe. We'll cover this when it
ABOVE: The proposed gluccotrack implantable CBGM next to some American
dimes to give scale. BELOW: Roche's CGM and MySugr app on iphone.